Prestige Biologics Co., Ltd. (KOSDAQ:334970)

Market Cap	318.19B
Revenue (ttm)	3.87B
Net Income (ttm)	-41.26B
Shares Out	77.42M
EPS (ttm)	-627.79
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	185,711
Average Volume	112,506
Open	4,080.00
Previous Close	4,110.00
Day's Range	3,905.00 - 4,180.00
52-Week Range	3,905.00 - 7,830.00
Beta	1.08
RSI	39.49
Earnings Date	n/a

About Prestige Biologics

Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd. was formerly known...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 334970

Financial Performance

In 2024, Prestige Biologics's revenue was 2.17 billion, an increase of 24.24% compared to the previous year's 1.75 billion. Losses were -29.37 billion, -25.53% less than in 2023.